TransCode Therapeutics Inc.

RNAZ | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.76

+$0.11 (+6.67%)

At close: Sep 21, 2026, 4:00 PM ET

$1.84

+$0.08 (+4.55%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+6.67%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.86M

1D Range

1.73 1.79

52W Range

1.58 20.99

Valuation (TTM)

PE 0

PB -0.00

EV/EBITDA 217.43

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target N/A

Cash Flow

FCF Yield -267874.4%

SBC Adj. FCF Yield -262737.0%

SBC Impact -1.9%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -116.8% | 47.1%

FCF 3Y | 5Y -148.7% | -98.5%

Returns

ROA -28.3%

ROE -58.1%

ROIC -23.7%

Financial Health

Net Cash

$7.73B

Current Ratio 1.97

Interest Coverage -5,337.75

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease....

Sector Healthcare

Industry Biotechnology

Employees 12

IPO Date Jul 7, 2021

Website www.transcodetherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.